INTRODUCTION AND OBJECTIVES: Post prostatectomy incontinence (PPI) can have a drastic impact on quality of life. In reported literature, the natural history of men with moderate to severe PPI has not been adequately studied. Our aim was to better predict which patients would benefit from prompt surgical interventions for incontinence. We hypothesized that men using >3 pads after surgery would be much less likely to regain continence and would be most bothered by their symptoms.
INTRODUCTION AND OBJECTIVES: Post prostatectomy incontinence (PPI) can have a drastic impact on quality of life. In reported literature, the natural history of men with moderate to severe PPI has not been adequately studied. Our aim was to better predict which patients would benefit from prompt surgical interventions for incontinence. We hypothesized that men using >3 pads after surgery would be much less likely to regain continence and would be most bothered by their symptoms.
METHODS: The study population included men with localized prostate cancer treated with radical prostatectomy at a single center from December 1999 to April 2018. After IRB approval, EPIC-26 and UCLA quality of life surveys were completed at multiple time points post-op, up to 60-month follow-up. Associations between health outcomes and pad use were assessed using Pearson's chi square tests. Post-surgery improvement in urinary control and quality of life were modeled using multinomial logistic regression.
RESULTS: A total of 1,568 patients were assessed at 30 months and 689 at 60 months post-op. At one-month following surgery, 1,034 reported using <3 pads and 534 reported >3 pads. Patients using <3 pads post-surgery were 7.17 times more likely to become continent (0-1 pad) by month 30 compared to patients using >3 pads (95% CI 5.151, 9.991). The probability of a severely incontinent patient regaining continence by month 30 was .12, while those using <3 pads had a .88 probability of obtaining continence. Of those that weren't lost to follow-up, the probability of continence by month 60 remained stable at .13 and .87, for those using >3 and <3 pads respectively. Age was not significantly associated with continence in the >3 pad group.
Patients requiring >3 pads reported lower quality of life scores. High bother score at any time post-surgery was significantly associated with using more than 3 pads (p<.0001). Patients using <3 pads were 3.572 times more likely to improve in bother score by month 30 (95% CI 2.734,4.668). The probability of improvement in bother score in a patient who used >3 pads was .22, compared to .78 in patients using <3 pads.
CONCLUSIONS: Based on our data, the status of urinary control in the first month following radical prostatectomy, assessed by quantitative pad counts and qualitative reports of symptoms, can predict long term outcomes. Patients requiring >3 pads are less likely to recover continence and continue to report high bother scores long after prostatectomy. This cohort should be appropriately counseled as they may benefit from early surgical interventions for PPI.
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PD32-05 APPLICATION OF HYALURONIC ACID/CARBOXYMETHYL CELLULOSE MEMBRANE FOR EARLY CONTINENCE AFTER NERVE-SPARING ROBOT-ASSISTED RADICAL PROSTATECTOMY
Nobuyuki Hinata*, Yukari Bando, Tomoaki Terakawa, Junya Furukawa, Yuzo Nakano, Masato Fujisawa, Kobe, Japan INTRODUCTION AND OBJECTIVES: To assess whether application of a hyaluronic acid-carboxymethyl cellulose membrane (HA/CMC) to the prostate bed and neurovascular plate facilitated early return of continence after nerve-sparing robot-assisted radical prostatectomy (RARP).
METHODS: The subjects were 183 consecutive patients with organ-confined prostate cancer who underwent unilateral or bilateral nerve-sparing RARP. After vesicourethral anastomosis, HA/CMC was placed to cover Denonvilliers' fascia (behind the anastomotic suture) and the preserved neurovascular plate. The time until complete continence after RARP and perioperative complications were compared between patients with or without HA/CMC. RESULTS: HA/CMC was applied in 13/46 patients (28.3%) receiving bilateral nerve-sparing surgery and 40/137 patients (29.2%) receiving unilateral nerve-sparing surgery. After bilateral nerve-sparing RARP, the median time until continence was significantly shorter in patients with HA/CMC than in those without HA/CMC (3.2 vs. 9.3 months, respectively, p < 0.01). After unilateral nerve-sparing RARP, the median time until continence was also significantly shorter in patients with HA/CMC than in those without HA/CMC (3.2 vs. 12.0 months, respectively, p < 0.01). Multivariate Cox proportional hazards regression analysis showed that an age < 70 years (hazard ratio [HR]: 1.74, 95% confidence interval [CI]: 1.12-2.80), institutional caseload > 200, (HR: 1.64, 95%CI: 1.10-2.47), and use of HA/CMC (HR: 1.84, 95%CI: 1.22-2.76) were independent predictors of early postoperative continence. Complication rates, including urinary leakage, did not differ significantly between patients with or without HA/CMC. CONCLUSIONS: Application of HA/CMC to the prostate bed and neurovascular plate resulted in significantly faster postoperative return of continence after both unilateral and bilateral nervesparing RARP.
INTRODUCTION AND OBJECTIVES:
The artificial urinary sphincter (AUS) is the standard treatment of male urinary incontinence (SUI) and has the longest efficacy record. However, revision rates are reported in up to a third of the cases. Revision and explanation rates dues to urethral atrophy and cuff erosion vary considerably among published studies. In addition to general risk factors, this may be attributed to high occlusion pressures. The aim is to determine the safety and efficacy of a novel AUS.
METHODS: VICTO is a single unit pre-connected adjustable device with an occluding cuff (OC), a pressure regulating balloon and a scrotal pump with a self-sealing port for pressure adjustment. VICTOplus has additionally a stress relief balloon to transmit transient intraabdominal pressure changes to the OC. The regulating pressure is adjustable in the range 0-100 cmH2O and can be altered at any time after implantation by injection or removal of fluid. In the time between 12/2016 and 10/2018 the device was indicated in 52 patients with SUI after prostate surgery (prostatectomy n[45; transurethral prostate resection n[4; traumata[3). We included the data from 45 patients (VICTO n[18, VICTOplus n[27) with a mean follow-up time of 10.1 months (range 1.2-21.1). Patients with more than 2 prior incontinence surgeries were excluded (n[2) and 5 systems were not activated at the time of the data collection. We used a telephone questionnaire to collect postoperative data as daily pad use and satisfaction rate. Average age at time of implantation was 69.5 (AE 9.7) years. There were between 1 to 5 (IQR[1.5, M[1) readjustment needed to achieve a sufficient result.
RESULTS: In all 45 cases the device was easily implanted without any intraoperative complications. One patient with persistent incontinence after VICTO-Implantation required a smaller OC. The pad per day usage improved from 6.4 (AE3.5) to 1.6 (AE1) and the continence rate (max. 1p/d) was 53.3%. The overall satisfaction was 83.8% and 88.6% would undergo the same operation again. Only 4 patients had an improvement less than 50%, all of them are not fully activated yet and may improve more with future adjustments.
CONCLUSIONS: The device provides adjustability in regulating pressure in situ. In our cohort of 45 patients, 91.1% had at least an improvement of 50% and these short results are promising and challenge prior AUS series. Adjusting the system pressure to the lowest level providing continence may reduce the long-term rate of erosions and "subcuff atrophy", however such data are not yet available. shown that men with low serum testosterone appear to have a higher risk of artificial urinary sphincter (AUS) cuff erosion. However, the urethral sequelae of androgen deprivation therapy (ADT) among AUS patients have not been well studied. We hypothesized that men on ADT for advanced prostate cancer may be at increased risk for urethral atrophy and AUS complications.
METHODS: In our large AUS database of cases performed by a single surgeon 2007-2018 at a tertiary urban medical center, we identified two group of men: those who had received ADT (typically with radiation) and those with known normal serum testosterone (T) levels without a history of ADT or radiation. Demographic and outcome data were collected and analyzed to determine trends in cuff sizes used in these men and rates of urethral erosion. Use of a 3.5 cm AUS cuff was defined as a surrogate for urethral atrophy and compared between groups.
RESULTS: From our database of 643 AUS cases during the study interval, we identified 67 (10.4%) who had been on ADT and 32 (5%) with normal T and no history of prior ADT or radiation. In these groups, 17 (26.2%) men on ADT developed AUS cuff erosion compared with 1 (3.7%) in the normal T group, which was significant on univariate analysis (p[0.02). A 3.5 cm AUS cuff was utilized more commonly among the ADT group (32/67, 48.5%) compared with the control group (9/32, 28.1%, p[0.08). Among men with 3.5 cm cuffs, the rates of urethral erosion were significantly higher among men who had been on ADT (31.2%) compared with the control group (11.1%, p[0.04) .
CONCLUSIONS: Men with a history of ADT appear to have a greater likelihood of urethral atrophy, as manifested by increased use of 3.5 cm AUS cuff. This further supports the adverse relationship between hypogonadism and urethral homeostasis, which may contribute to increased rates of AUS cuff erosion. AUS patients receiving ADT for advanced prostate cancer should be counseled appropriately regarding this elevated risk. 
